Agenus Reports 48% Estimated Three-Year Survival with BOT+BAL in Recurrent Ovarian Cancer

Agenus Inc. announced three-year follow-up results from the ovarian cancer cohort of its Phase 1b C-800-01 trial, showing an estimated 48% survival at both two and three years for patients treated with botensilimab (BOT) in combination with balstilimab (BAL). These durable clinical benefits were observed in a heavily pretreated population with recurrent ovarian cancer, including those with platinum-sensitive and platinum-resistant or refractory disease. The findings were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting.